 
 
 
Protocol J2X-MC -PYAJ 
 
 
A prospective cohort study to evaluate the real -world effectiveness of 
bamlanivimab in participants with mild-to -moderate COVID -19 at 
high risk for progressing to severe illness, with matched controls . 
  
[STUDY_ID_REMOVED]  
 
 
Approval Date: 18-Dec -2020 
CONFIDENTIAL Protocol  J2X-MC-PYAJ
1Title Page
Confidential Information
The information contained in this document is confidential and is intended for the use of clinical investigators. It is the p roperty of 
Eli Lilly and Company or its subsidiaries and should not be copied by or distributed to persons not involved in the clin ical 
investigation of bamlanivimab ( LY3819253 ), unless such persons are bound by a confidentiality agreement with Eli Lilly and 
Company or its subsidiaries. 
Note to Regulatory Authorities: This document may contain protected personal data and/or commerci ally confidential information 
exempt from public disclosure. Eli Lilly and Company requests consultation regarding release/redaction prior to any public re lease. 
In the United States, this document is subject to Freedom of Information Act (FOIA) Exemption 4 and may not be reproduced or 
otherwise disseminated without the written approval of Eli Lilly and Company or its subsidiaries .
Protocol Title:
A prospective cohort study  to eval uate the real -world effect iveness of bamlanivimab in 
participants wi th mild-to-moderate COVID -19 at high risk for progressing to severe illness, with 
matched controls
Protocol Number: J2X- MC-PYAJ
Compound (s): bamlanivimab (LY3819253 )
Study Phase: 2
Short Title: A prospective cohort study  to eval uate the effect iveness in the real -world setting of 
bamlanivimab in participants with mild -to-moderate COVID -19 at high risk for 
progressing to severe illness, with matched controls
Sponsor Name: Eli Lilly  and Com pany
Legal Registered Address: Indianapo lis, Indiana ,USA 46285
Regulatory Agency Identifier Number(s ):
IND: 150440
Approval Date: Protocol Electronically Signed and Approved by Lilly ondate provi ded bel ow.
Approval Date: 18-Dec-2020 GMT
CONFIDENTIAL Protocol  J2X-MC-PYAJ
2Medical Monitor Name and Contact Information will be provided separately .
CONFIDENTIAL Protocol  J2X-MC-PYAJ
3Table of Contents
1. Protocol Summary ...................................................................................................... 6
1.1. Synopsis ....................................................................................................................... 6
1.2. Schema ......................................................................................................................... 9
1.3. Schedule of Act ivities (SoA) ...................................................................................... 10
2. Introduction .............................................................................................................. 13
2.1. Study  Rati onale .......................................................................................................... 13
2.2. Background ................................................................................................................ 13
2.3. Benefit/Risk Assessment ............................................................................................ 13
3. Objectives and Endpoints ......................................................................................... 15
4. Study Design ............................................................................................................. 16
4.1. Overall Design ............................................................................................................ 16
4.2. Scientific Rati onale f or Study  Design ......................................................................... 17
4.3. Justification for Dose .................................................................................................. 18
4.4. End of Study  Definit ion.............................................................................................. 18
5. Study Population ...................................................................................................... 19
5.1. Inclusio n Cri teria........................................................................................................ 19
5.2. Exclu sion Criteria....................................................................................................... 20
5.3. Matched controls ........................................................................................................ 21
5.4. Lifest yle Considerat ions............................................................................................. 22
5.5. Screen Failures ........................................................................................................... 22
6. Study Intervention .................................................................................................... 23
6.1. Study  Intervent ion(s) Administered ............................................................................ 23
6.1.1. Speci al Treatm ent Consi derat ions............................................................................... 23
6.1.2. Temporary  Stopping Cri teria...................................................................................... 24
6.2. Preparati on/Handling/Storage/Accountabilit y............................................................. 25
6.3. Measures to Minimize Bias: Rando mizat ion and Blinding .......................................... 25
6.4. Study  Intervent ion Compliance ................................................................................... 25
6.5. Concomitant Therapy .................................................................................................25
6.6. Dose Modificat ions.................................................................................................... 26
6.7. Intervention after the End of the Study ........................................................................ 26
7. Discontinuation of Study Intervention and Participant 
Discontinuation/Withdrawal .................................................................................... 27
7.1. Discontinuati on of  Study  Intervent ion........................................................................ 27
7.2. Parti cipant Discontinuation/Wit hdrawal fro m the Study ............................................. 27
7.2.1. Discontinuati on of  Inad vertent ly Enrolled Participants ............................................... 27
7.3. Lost to Follow -Up...................................................................................................... 28
8. Study Assessments and Procedures ......................................................................... 29
8.1. Efficacy Assessments .................................................................................................29
8.2. Safety Assessments .................................................................................................... 29
8.2.1. Vital Signs.................................................................................................................. 29
8.2.2. Hospitalization Events ................................................................................................ 29
8.3. Adverse Events and Serious Adverse Events .............................................................. 30
CONFIDENTIAL Protocol  J2X-MC-PYAJ
48.3.1. Time Period and Frequency  for Collect ing AE and SAE 
Inform ation................................................................................................................. 30
8.3.2. Method of Detecting AEs and SAEs ........................................................................... 30
8.3.3. Follow-Up of AEs and SAEs ...................................................................................... 31
8.3.4. Regulatory  Reporting Requirements for SAEs ............................................................ 31
8.3.5. Pregnancy ................................................................................................................... 31
8.3.6. Hypersensi tivity Reacti ons......................................................................................... 31
8.3.7. Infusio n-related Reacti ons .......................................................................................... 31
8.3.8. Product Com plaint s.................................................................................................... 32
8.4. Treatment of Overdose ............................................................................................... 33
8.5. Pharmacokinet ics........................................................................................................ 33
8.6. Pharmacodynamics ..................................................................................................... 33
8.7. Genet ics..................................................................................................................... 33
8.8. Biomarkers ................................................................................................................. 33
8.9. Immunogenicit y Assessments ..................................................................................... 33
8.10. Health Economics ....................................................................................................... 33
9. Statistical Considerations ......................................................................................... 34
9.1. Statistical Hypotheses .................................................................................................34
9.2. Sample Si ze Determinat ion......................................................................................... 34
9.3. Popul ations for Analyses ............................................................................................ 34
9.4. Statistical Analyses ..................................................................................................... 34
9.4.1. P rimary Endpo int........................................................................................................ 35
9.4.2. Exploratory  Analyses .................................................................................................. 35
9.4.3. Subgroup Analyses ..................................................................................................... 36
9.5. Interim Analyses ......................................................................................................... 36
10. Supporting Documentation and Operational Considerations ................................ 37
10.1. Appendix 1: Regulatory , Ethical , and Study  Oversight 
Considerations ............................................................................................................ 37
10.1.1. Regulatory  and Ethi calConsiderat ions........................................................................ 37
10.1.2. Financial Disclo sure................................................................................................... 37
10.1.3. Inform ed Consent Process .......................................................................................... 37
10.1.4. Data Protection ........................................................................................................... 38
10.1.5. Disseminat ion of Clinical Study  Data ......................................................................... 39
10.1.6. Data Qualit y Assurance .............................................................................................. 39
10.1.7. Source Documents ...................................................................................................... 40
10.1.8. Study  and Si te Start and Cl osure ................................................................................. 41
10.1.9. Publicat ion Policy ....................................................................................................... 41
10.1.10. Invest igator Informat ion............................................................................................. 41
10.1.11. Long -Term  Sample Retent ion..................................................................................... 41
10.2. Appendix 2: Adverse Events: Definit ions and Procedures for 
Recording, Evaluat ing, Follow -Up, and Reporting ...................................................... 42
10.2.1. Definit ion of AE......................................................................................................... 42
10.2.2. Definit ion of SAE ....................................................................................................... 43
10.2.3. Recording and Fo llow-Up of AE and/or SAE ............................................................. 44
10.2.4. Reporting of SAEs ...................................................................................................... 46
10.2.5. Medicat ion Error ........................................................................................................ 46
CONFIDENTIAL Protocol  J2X-MC-PYAJ
510.3. Appendix 3: Contraceptive Guidance and Co llection of 
Pregnancy Information ............................................................................................... 47
10.4. Appendix 4: Abbreviat ions......................................................................................... 51
11. References ................................................................................................................. 54
CONFIDENTIAL Protocol  J2X-MC-PYAJ
61. Protocol Summary
1.1. Synopsis
Protocol Title: A prospective cohort study  to evaluate the real -world effect iveness of 
bamlanivimab in participants with mild -to-moderate COVID -19 at high risk for progressing to 
severe illness, with matched controls
Rationale:
This study  aims to characterize the real -world effectiveness of bamlanivimab in participants with 
mild-to-moderate COVID -19 in adults and adolescents (age ≥12) who are at high risk of 
progressing to severe COVID -19 and/or hospitalization co mpared to a similar control population.
Objectives and Endpoints : 
Objectives Endpoints
Primary
To determine the proportion of patients with 
COVID -related hospitalization or death by 29 days 
among bamlanivimab -
treated participants 
compared to external controls.Proportio n (percentage) of participants who 
experience COVID -19 related hospitalization 
(defined as ≥24 hours of acute care )or death by
Day 
29
Secondary
To determine the proportion of patients with 
COVID -related hospitalization up to 60 and 90 
daysamong bamlanivimab -treated participants 
compared to external controls.COVID -19-related hospitalization ,defined as ≥24 
hours of acute care ,up to Days 60 and 90
To determine the proportion of patient swith a 
COVID -related ED visit through Days 29, 60, and 
90.ED visits for COVID -related causes
To describe the safety of bamlanivimab -treated 
participants through Days 29, 60 ,and 90.Adverse events or serious adverse events
Abbreviation: ED = emergency department .
CONFIDENTIAL Protocol  J2X-MC-PYAJ
7Overall Design :
An o pen-label, single -arm, prospective, cohort study  using m atched real -world external  control s. 
There i s no pl acebo arm . 
Design Outline
Screening
Interested participants or their legally  authori zed representative will sign the appropriate 
inform ed consent and child/adolescent assent document(s), as appropriate, prior to completion of 
any procedures.
The investigator will confirm a posit ive RT-PCR test or anti gen testing confirmat ionfor 
COVID -19(if ant igen test is accompanied by symptoms suggest ive of SARS -CoV -2 infection),
and review criteria for high risk under the EUA to confirm eligibilit y. 
Treatment and Assessment Period
This is the general sequence of events during the treatment and assessment period:
complete baseline procedures to confirm eligibilit y per inclusio n and exclusio n criteria 
and high -risk cri teria per EUA
participants receive infusio n of bamlanivimab, and
complete all safet y monitoring and post -infusio n data collect ion.
This table describes the visit t ypes
Study Day Visit Type
1 Bamlanivimab infusion at site 
24 hours (+1 day) Telepho ne contact 
29(±5 days), 60 (± 7 days) , 90 (± 7 days) EMR review and/orphone call 
Early  discontinuation and follow -up Telepho ne contact
If a participant is hospitalized, procedures and assessments will cont inue per the SoA. 
This table describes d ischarge fro m hospi talscenarios if an outpatient is subsequent ly 
hospi talized.
Discharge from Hospital (Outpatients Subsequently Hospitalized)
If hospital discharge … Then…
Occurs prior to Day 29 Participants will be asked to complete the remaining 
study assessments at the timepoints indicated in the 
SoA.
Occurs on the same day as a study assessment visit Assessments do not need to be repeated if the study 
assessments occurred within 8 hours of discharge and 
there has been no change in clinical status and the 
information is available to the site.
Does not occur at or prior to Day 28 Assessments will continue to occur up to Day 90 or 
until hospi tal discharge, w hichever is later.
Post- treatment Follow -Up
CONFIDENTIAL Protocol  J2X-MC-PYAJ
8Post-infusio nfollow-up assessments will be conducted at Days2, 28, 60, and 90 to assess 
clinical status and for adverse events.
Disclosure Statement : This is a treatm ent study . 
Number of Participant s:
The init ial plan is to enroll up to 3000 participants in the treated cohort over 4 -6 weeks of 
enrollment, with the same number in the control cohort. 
Data Monitoring Committee: No
CONFIDENTIAL Protocol  J2X-MC-PYAJ
91.2. Schema
The fo llowing figure illustrates the study  design for parti cipants receiving bamlanivimab .
aScreening and Day 1 procedures may occur on the same day .
bTelepho ne call 24 hours post -infusion .
cEMR review and/or phone call.
Note: Matched controls will include NM Health Members who have EMR and claims data to determine positive 
COVID test and any subsequent healthcare utilization, including hospitalization and death data ,to determine 
meeting of entry criteria such as mild/moderate symptoms.

CONFIDENTIAL Protocol  J2X-MC-PYAJ
101.3. Schedule of Activities (SoA)
Visits may be conducted as a telephone call or EMR review , as long as the protocol SoA is fo llowed. Refer to the study  day and visi t 
type table in Sect ion 4.1for addi tional clarificat ion.
This SoA i s for parti cipants receiving bamlanivimab only .
Study 
J2X-MC -PYAJ Screen Infusion Day
Study Day 1 2 29 60 90 EDScreening and Day 1 procedures may occur on the same day.
Day 2 = telephone call 24 hours post -infusion
Day 29, 60, 90 = EMR and/or telephone call review as necessary
Visit Window
(± number of days)-- 2* 5 7 7Visits may not be combined.
*Day 2 call visit window +2 only
Procedures
Informed consent X
Inclusion and 
exclusion criteria 
reviewX
Demographics X Including age, gender, race, ethnicity 
Preexisting 
conditio ns and 
medical historyXObtained from interview or available information.
Includes timing of exposure and onset of symptoms suggestive of 
SARS -CoV -2 infection, and risk factors and comorbidities associated 
with severe COVID -19 illness. 
Height X
Weight X
Prior treatments 
of special interest 
within the last 30 
daysXNSAIDs, antivirals, antibiotics, anti -malarials, corticosteroids, 
immunomodulators ,or other investigational treatments.
Tobacco use X
Concomitant 
medicationsX X X X X
CONFIDENTIAL Protocol  J2X-MC-PYAJ
11Study 
J2X-MC -PYAJ Screen Infusion Day
Study Day 1 2 29 60 90 EDScreening and Day 1 procedures may occur on the same day.
Day 2 = telephone call 24 hours post -infusion
Day 29, 60, 90 = EMR and/or telephone call review as necessary
Visit Window
(± number of days)-- 2* 5 7 7Visits may not be combined.
*Day 2 call visit window +2 only
SAEs/AEs X X X X X X XAny events that occur after signing the informed consent are considered 
SAEs/AEs as defined in Section 10.2.
Hospitalization , ED visits, and deaths from COVID -19 are captured as 
endpoints and not as SAE s.
SAEs/AEs will also be collected at the time of early discontinuation , if 
applica ble.
Physical 
examinationX
Vital signs XIncludes: body temperature, pulse rate, BP, respiratory rate, SpO2, and 
supplemental oxygen flow rate, FiO2 if known, and method of delivery, 
if applicable.
Record SpO2 while participant is at rest.
Day 1 recom mended timing of vitals: 
1. immediately before the infusion 
2. every 15 minutes during the infusion, as possible, and
3. every 30 minutes for at least 1 hour after the infusion.
During infusion, record pulse rate, BP and SpO2. Automation may be 
used. See Section 8.2.2 for data collected on CRF.
CONFIDENTIAL Protocol  J2X-MC-PYAJ
12Study 
J2X-MC -PYAJ Screen Infusion Day
Study Day 1 2 29 60 90 EDScreening and Day 1 procedures may occur on the same day.
Day 2 = telephone call 24 hours post -infusion
Day 29, 60, 90 = EMR and/or telephone call review as necessary
Visit Window
(± number of days)-- 2* 5 7 7Visits may not be combined.
*Day 2 call visit window +2 only
Hospitalization 
eventsX* X X X X X*Post -infusion only (otherwise exclusion criterion )
Record if the following events occur or occurred since prior 
visit:
Emergency room visits
hospitalized
ICU admittance, 
Extended care facility admittance, and
Discharge
Death X X X X X X From COVID -19-related causes
Abbreviations: AE = adverse event; BP = blood pressure; CRF = case report form; ED = early discontinuation ; FiO2 = fraction of inspired oxygen in the air; ICU 
= intensive care unit; NSAIDS = non -steroidal anti -inflammatory drugs; SpO2 = saturation of peripheral oxygen.
CONFIDENTIAL Protocol  J2X-MC-PYAJ
132. Introduction
2.1. Study Rationale
The efficient communit y spread of SARS -CoV -2 has resulted in the current pandemic of 
COVID -19, whi ch in severe and crit ical cases results in progressive pulmo nary infect ion, 
complicated by  respi ratory  failure, wi th a high prevalence of acute respiratory  distress syndro me. 
Although several therapies have been explored in severe COVID -19, none have improved 
survival, including antivirals, glucocortico ids, and immunoglobulins (Liu et al 2020). 
This study  aims to characterize the real -world effectiveness of ba mlanivimab in participants with 
mild-to-moderate COVID -19 in adults adolescents (age ≥12) who are at high risk of progressing 
to severe COVID -19 and/or hospi talizat ion compared to a similar control populat ion.
2.2. Background
The SARS -CoV -2gains entry  to cells through binding of the spike (S) protein to ACE2 receptors 
on cells ( Hoffmann 2020). Eli Lilly and Company has a partnership with AbCellera Bio logics 
Inc. (AbCellera; Vancouver, Canada) to develop neutralizing IgG1 mAbs to the spike(S) protein 
of SARS -CoV-2 as a potential treatment for COVID- 19. Candidate ant ibody  gene sequences 
have been selected from a recent ly recovered COVID -19 USpatient’s serum using AbCellera’s 
core pl atform screening techno logies.
2.3. Benefit/Risk Assessment
Anticipated risk is considered low and is based on the known mechanism o f action for hum an-
derived neutralizing ant ibodies in acute viral disease states. A theoretical risk is that this 
intervent ion may cause ADE of viral replication. This is based on responses observed to so me 
monoclonal antibody  therapies used in other unrelated viral diseases. Unlike ADE associated 
with dengue and Zika virus infect ions, this phenomenon has not been clearly  established for 
coronavirus infect ions, such as SARS and Middle East respiratory  
syndrome, and has not been 
reported to date with SARS -CoV -2. Addit ionally, limited experience with the use of 
convalescent serum as a treatment for patients with severe COVID -19 di sease has not indicated 
safet y concerns (Shen et al.2020; Duan et al. 2020). 
The risk of clinical ADE for either intervention or in combinat ion is considered low due to 
the absence of ADE fro m in vit ro studies, and
the absence of ADE fro m in vivo nonhuman primate studies for bamlanivimab.
To date, there is no evidence of productive enhancem ent of  ADE wi th SARS -CoV -2. 
Addit ional manageable risks associated with most therapeutic monoclo nal ant ibodies are the 
potenti al for infusi on-related hy persensi tivity and cy tokine release react ions. The single infusio n 
in this study  will be admin istered at a controlled rate, the study  parti cipants will be m onitored 
closely , and adj ustm ents in the infusion rate will be made and/or the infusio n stopped, if 
indicated. Addit ional informat ion regarding infusion reaction management options is located in
Secti on 6.1.1.2 .
CONFIDENTIAL Protocol  J2X-MC-PYAJ
14Given the totalit y of data on bamlanivimab, the well -established safety  profile of other 
therapeuti c mAbs, and the lack of disease -directed therape utic opti ons f or pati ents wi th COVID -
19 illness or to prevent the SARS -CoV -2 infect ion, the overall benefit or risk assessment of this 
study  is considered favorable.
More detailed informat ion about the known and expected benefits and risks and reasonably 
expected adverse events of bamlanivimab may be found i n the IB.
CONFIDENTIAL Protocol  J2X-MC-PYAJ
153. Objectives and Endpoints
Objectives Endpoints
Primary
To determine the proportion of patients with 
COVID -related hospitalization or death by 29days 
among bamlanivimab -treated participants 
compared to external controls.Proportio n (percentage) of participants who 
experience COVID -19related hospitalization
(defined as ≥24 hours of acute care )or death by
Day 
29
Secondary
To determine the proportion of patients with 
COVID -related hospitalization up to 60 and 90 
days among bamlanivimab -treated participants 
compared to external controls.COVID -19-related hospitalization ,defined as ≥24 
hours of acute care ,up to Days60 and 9 0
To determine the proportion of patients with a 
COVID -related ED visit through Days 29, 60 ,and 
90.ED visits for COVID -related causes
To describe the safety of bamlanivimab -treated 
participants through Days 29, 60 ,and 90 .Adverse events or serious adverse events
Abbreviation : ED = emergency department.
CONFIDENTIAL Protocol  J2X-MC-PYAJ
164. Study Design
4.1. Overall Design
This study  is being conducted inthe same popul ation as in the Emergency Use Authorizat ion 
(EUA [FDA 2020 a]). 
Study  J2X-MC-PYAJis an o pen-label, single -arm, prospective, cohort study using matched real -
world external controls. There is no placebo arm.
Screening
Interested participants or their legally  authori zed representative will sign the appropriate 
inform ed consent and child or adolescent assent document(s), as appropriate, prior to complet ion 
of any procedures. The participant may enter the study with a previous positive SARS -CoV -2 
viral test result fro m an external test ing facilit y.This test result must be the first time the 
participant has had a posi tive RT-PCR or anti gen testing confirmat ion for COVID -19 (if antigen 
test i s acco mpanied by symptoms suggestive of SARS -CoV -2 infect ion)for SARS -CoV -2. 
Prescreening prior to administration of bamlanivimab may be conducted to collect baseline 
inform ation.
The invest igator will review symptoms, risk factors ,and other non -invasive inclusio n and 
exclusio n criteria pri or to any  invasive procedures. If the participant is eligible after this review, 
then the site will perform the invasive procedures .
Trea tment and Assessment Period
This is the general sequence of events during the treatment and assessment period:
complete baseline procedures to confirm eligibilit y (posit ive COVID -19 test, hi gh-risk 
criteria per EUA )
participants receive study  intervent ion,and
complete all safet y monitoring and post -infusio n data collect ion. 
Treat ed population visit types
This table describes the visit t ypes for the treatm ent popul ation for this study .
Study day Activity Visit type
Up to 10 
daysbefore 
infusionPositive COVID -19 test
Confirm high -risk criteria per EUAAmbulatory setting
1Infusion Ambulatory setting
2AEor SAE data collection (24 hours 
post-infusion) 
Endpoints including hospitalization 
or ED visit for COVID -19Telepho ne call 
CONFIDENTIAL Protocol  J2X-MC-PYAJ
1729AEor SAE data collection
Primary  endpoint collection —
hospitalization for COVID -
19; EMR and/or telephone call
60, 90AEor SAE data collection
Endpoints including hospitalization 
or ED visit for COVID -19Electronic and/or telephone call
Abbreviations: AE = adverse event; ED = emergency department ; EUA = emergency use authorization; SAE = 
serious adverse event.
Guidelines if a participant is hospitalized
If a participant is hospitalized, procedures and assessments will cont inue per the SoA (Secti on 
1.3). 
This table describes d ischarge fro m hospi talscenarios if an outpatient is subsequent ly 
hospi talized.
If hospital discharge … Then
…
Occurs prior to Day 29 Participants will be asked to complete the remaining 
study assessments at the timepoints indicated in the 
SoA.
Occurs on the same day as a study assessment visit Assessments do not need to be repeated if the study 
assessments occur red within 8 hours of discharge ,and 
there has been no change in clinical status and the 
information is available to the site .
Does not occur at or prior to Day 29 Assessments will continue to occur up to Day 90 or 
until hospital discharge, w hichever is later.
Abbreviation: SoA = schedule of activities.
Post-treatment follow -up
Post-treatm ent follow-up assessments will be conducted at Days2, 29,60, and 90 to assess study 
endpo ints.
4.2. Scientific Rationale for Study Design
Overall Design
This study  is designed to characterize the real -world effect iveness o f bamlanivimab in 
participants wi th mild-to-moderate COVID -19 in adults and children who are at high risk of 
progressing to severe COVID -19 and/or hospitalization co mpared to a similar co ntrol populati on.
Participant Characteristics
The parti cipant population are those infected with SARS -CoV -2 who are at high risk of 
developing severe disease requiring hospitalizat ion. There is historical evidence that patients 
infected with upper respirat ory viruses who are treated early  in thei r disease course have better 
responses to anti -viral therapies (Aoki  etal., 2003); all pat ients in the treated cohort will receive 
an infusio n of bamlanivimab wit hin 10 days of their posit ive COVID -19 test.
CONFIDENTIAL Protocol  J2X-MC-PYAJ
18The pop ulation of participants with mild -to-moderate COVID -19 illness who are at high risk of 
developing severe disease per the EUA was chosen to evaluate if effect ive ant iviral antibody 
therapy  may prevent progressi on to the severe form o f COVID -19 illness by treating this 
popul ation early in their disease course and prior to respiratory  com promise and failure. 
Parti cipants wi th these ri sk factors are at higher risk for more severe disease and hospitalizat ion. 
This populat ion was chosen to evaluate if effective antiviral ant ibody  therapy  may prevent 
hospi talizati on or death . 
4.3. Justification for Dose
Bamlanivimab -700 m g was est imated as the maximum therapeut ic dose based on PK/PD viral 
dynamics modeling of Study  J2W-MC-PYAB and has a sustained concentration above the in 
vitro IC90 of viral cell -entry  neutralizat ion in the lung tissue (95th percent ile of the est imates 
used) for at least 28 day s in 90% of the participant populat ion.
4.4. End of Study Definition
A participant is considered to have co mpleted the study  if they have completed all required 
phases of the study  including the last scheduled procedure shown in the S oA (Section 1.3).
The end o f the study  is defined as the date of last scheduled procedure shown in the So A
(Secti on 1.3)for the last participant in the trial.
CONFIDENTIAL Protocol  J2X-MC-PYAJ
195. Study Population
Prospective approval o f protocol  deviati ons to recrui tment and enro llment criteria, also known as 
protocol  waivers or exempt ions, is not permitted.
Due to the crit icality of part icipant health, verbal interview of the potential participant, or their
legal representative or family member, may  be the source for disease characterist ics and medical 
history , unless otherwise specified within the eligibilit y criteria.
5.1. Inclusion Criteria
Parti cipants are eligible to be included in the study only if all o fthe following criteria apply:
Age
1. A re ≥12years of age at the time of screening
Disease Characteristics
2.Are current ly not hospi talized
3.Have one or more mild or moderate COVID -19 symptoms (FDA resource page, available
at: https://www .fda.gov/regul atory -information/search -fda-guidance -docum ents/covid -
19-developing -drugs -and-biological -products -treatment - or-prevent ion) 
i.Fever
ii.Cough
iii.Sore throat
iv.Malaise
v.Headache
vi.Muscle pain 
vii. Gastrointestinal symptoms, or
viii. Shortness o f breath with exert ion
4.Must have first positive SARS -CoV -2 viral infect ion determinat ion and as soon as 
possible within 10 days of symptom  onset
5.Are males or non -breastfeeding females
Reproductive and Contraceptive agreements and guidance is provided in Section 10.3,
Appendix 3.Contraceptive use by males or females should be consistent with local 
regul ations for those participat ing in clinical studies
Study Procedures
6.Unde rstand and agree to comply  with planned study  procedures
CONFIDENTIAL Protocol  J2X-MC-PYAJ
20Informed Consent
7.The parti cipant or l egally  authori zed representative givessigned informed consent and/or 
assent as described in Section10.1.3 ,which includes compliance with the requirements 
and restrictions listed in the ICF and in this protocol
High risk as defined per EUA fact sheet : https://www.fda.gov/media/143603/download
8.For example, participants who meet at least 1of the fo llowing cri teria:
Have a BMI ≥35
Have chronic kidney disease
Have diabetes
Have immunosuppressive disease
Are current ly receiving immunosuppressive treatment
Are ≥65 years of age
Are ≥55 years of age AND have
•cardi ovascular di sease, OR
•hypertensio n, OR
•chronic obstructive pulmo nary disease or other chronic respiratory  
disease.
Are 12 –17 y ears of age AND have
•BMI ≥85th percent ile for thei r age and gender based on CDC 
growth charts, 
https://www.cdc.gov/growt hcharts/clinical_charts.ht m, OR
•sickle cell disease, OR
•congenital or acquired heart disease, OR
•neurodevelopmental disorders, for example, cerebral palsy, OR
•a medical -related techno logical dependence, for example, 
tracheostomy, gastrostomy , or posi tive pressure vent ilation (not 
related to COVID -19), OR
•asthma, reactive airway or other chronic respiratory disease that 
requi res daily medicat ion for con trol.
5.2. Excl usion Criteria 
Limitat ions of Benefit and Potential for Risk in Patients with Severe COVID -
19
Benefit of treatment with bamlanivimab has not been observed in pat ients hospitalized due to 
COVID -19. Monoclonal ant ibodies, such as bamlanivimab, may be associ ated wi th worse 
clinical outcomes when administered to hospitalized patients with COVID -19 requi ring high 
flow oxy gen or m echanical  ventilation.
More specifically, p articipants are excluded from the study  if any  of the f ollowing criteria apply:
Medical Con ditions
9.Parti cipants who:
a.are hospitalized due to COVID- 19, OR 
CONFIDENTIAL Protocol  J2X-MC-PYAJ
21b.requi re oxy gen therapy  due to COVID -19, OR 
c.requi re an increase in baseline oxygen flow rate due to COVID -19 in those on 
chronic oxy gen therapy  due to underlying non -COVID -19 rel ated comorbidity.
10.Have SpO2 ≤ 90% on room  air or PaO2/Fi O2 < 300, respiratory  rate ≥30 per minute, 
heart rate ≥125 per minute (FDA resource page, available at: 
https://www .fda.gov/regul atory -inform ation/search -fda-guidance -docum ents/covid -
19-
developing -drugs -and-biological -products -treatm ent- or-prevent ion) 
11.Have body  weight <40 kg.
12.Requi re mechanical vent ilation or anticipate dimpending need for m echanical  ventilation 
13.Have known allergies to any  of the com ponents used in the formulat ionof the 
intervent ions
14.Suspected or proven serious, active bacterial, fungal, viral, or other infect ion (besides 
COVID -19) that i n the opinio n of the invest igator could const itute a ri sk when taking 
intervent ion
15.Have any comorbidityrequi ring surgery  within <7 day s, or that i s considered life -
threatening within 29 days
16.Have any serious conco mitant sy stemic disease, condit ion,or disorder that, in the opinio n 
of the investigator, should preclude participat ion in this study
Other Exclusions
17.Have a history  of a posi tive SARS -CoV -2 serology test
18.Have a history  of a posi tive SARS -CoV -2 test prior to the one serving as eligibilit y for 
this study
19.Have received an invest igational intervent ion for SARS -CoV -2 prophylaxis wit hin 30 
days before dosing
20.Have received treatm ent wi th a SARS -CoV -2-specific mo noclonal ant ibody , rem desivi r, 
or other treatment for COVID -
19
21.Have received convalescent COVID -19 pl asma treatm ent 
22.Have part icipated in a previous SARS -CoV -2 vaccine study
23.Have part icipated, within the last 30 days, in a clinical study involving an invest igational 
intervent ion. If the previous invest igational intervent ion has a long half -life, 5 half -lives 
or 30 day s, whichever i s longer, shoul d have passed.
24. A reconcurrent ly enrolled in any other type of medical rese arch judged not to be
scientifically or medically co mpatible wit h this study
25.Are breast -feeding
26.Are invest igator site personnel directly affiliated wit h this study , and
5.3. Matched controls
Matched controls will include NM Healt h System  members who have EMR an d claims data to 
determine positive COVID test and any subsequent healt hcare utilizat ion, including 
hospi talizati on and death data. Data for control  participants will indicate that that they  aresimilar 
to treated participants according to COVID -19 symptoms and other study entry criteria. If 
applicable, non -NM Heal th System  members m ay be used as members of the control  
CONFIDENTIAL Protocol  J2X-MC-PYAJ
22popul ationbased on EMR review and matching to enro lled participants. A waiver of informed 
consent and HIPAA authorizat ion will be re quested for matched controls.
5.4. Lifestyle Considerations
Reproductive and Contraceptive guidance is provided in Section 10.3, Appendix 3.
5.5. Screen Failures
Screen failur es are defined as part icipants who consent to participate in the clinical study  but are 
not subsequently enrolled in the study . A minimal set of screen failure information is required to 
ensure transparent reporting of screen failure participants to meet the Consolidated Standards of 
Reporting Trials publishing requirements and to respond to queries from regulatory  authori ties. 
Minimal infor mation includes demography, screen failure details, eligibilit y criteria, and any 
SAE.
Individuals who do not meet the criteria for participation in this study  (screen failure ) may notbe 
rescreened.
CONFIDENTIAL Protocol  J2X-MC-PYAJ
236. Study Intervention
Study  intervent ion is defined as any invest igational intervent ion(s), m arketed product(s), 
placebo, or m edical device(s) intended to be administered to /used by a study  parti cipant 
according to the study  protocol .
6.1. Study Intervention(s) Administered
Each participant will receive a single IV in fusion of  bamlanivimab.
Study intervent ion must be administered within 10days of symptom  onset and following the first 
positive SARS -CoV -2 test sample collect ion.
Intervention name Bamlanivimab ( LY3819253 )
Dose formulation Solution
Dosage level (mg) 700
Use Experimental
IMP and NIMP IMP
Sourcing From Lilly
Packaging and labeling Study intervention will be 
provided in glass vials and 
will be labeled appropriately
Abbreviations: IMP = investigational medicinal product; IV = intravenous ; NIMP = non-investigational medicinal 
product .
Infusio n informat ion may be found in the pharmacy  manual .
The infusio n rate m ay be reduced as deemed necessary  if an infusio n react ion is observed 
(Secti on 6.1.1.2 ). Participants will be mo nitored for at least 1 hour after completion o f the 
infusio n. 
The site must have age -appropri ate resusci tation equi pment, em ergency drugs ,and appropriately 
training staff avai lable during the infusio n and for at least 1 hour after the complet ion of the 
infusio n.
Self-isolation procedures should be fo llowed per local  guidelines.
6.1.1. Special Treatment Considerations
6.1.1.1. Premedication for Infusions
Prem edicat ion for infusio ns is not pl anned. However, if an infusion react ion occurs during 
administration or if the participant has a medical history  suggesting a potential benefit from 
prem edicat ion, the study  invest igator(s) should determine the appropriate premedicat ion. The 
investigator sandsponsor may decide to usepremedicat ion if the frequency o f infusion react ions 
among parti cipants warrants i t.
If minor infusio n reactions are observed, administration of acetaminophen, 500 to 1000 mg, 
antihistamines ,and/or other appropriately indicated medicat ions may be given prior to the start 
of infusio ns for subsequent participants. 
CONFIDENTIAL Protocol  J2X-MC-PYAJ
24The decisio n to implement premedicat ion for infusio ns in subsequent participants will be made 
by the investigator and sponsor and r ecorded in the study  documentati on.
Any premedicat ions given will be documented as a concomitant therapy .
6.1.1.2. Management of Infusion Reactions
Access to medicat ions(e.g., epinephrine, norepinephrine, steroids, and diphenhydramine) for 
potenti al anaphylaxis a nd serious infusio n react ions is mandatory  at all  infusi on sites.
Symptoms and Signs
Symptom s and si gns that m ay occur as part of an infusio n reaction include, but are not limited to ,
fever, chills, nausea, headache, bronchospasm, hypotension, angioedema, throat irritation, rash
including urticaria , pruri tus, myalgia, and dizziness.
Infusio n-related reacti onseverit ywill be assessed and reported using the DAIDS Table for 
Grading the S everit y of Adult and Pediatric Adverse Events, version 2.1 (July  2017) . 
This table describes the severit y of react ions according to DAIDS. 
Parameter Mild Moderate Severe Severe and 
Potentially Life -
threatening
Acute 
Allergic 
ReactionLocalized urticaria
(wheals) with no medical 
interventio n indicatedLocalized urticaria 
with intervention 
indicated 
OR 
Mild angioedema 
with no intervention 
indicatedGeneralized 
urticaria
OR
Angioedema with 
interventio n 
indicated 
OR
Symptoms of mild 
bronchospasmAcute anaphylaxis 
OR 
Life-
threatening 
bronchospasm 
OR
Laryngeal edema
Source: DAIDS Table for Grading the Severity of Adult and Pediatric Adverse Events, Version 2.1 (July 2017).
6.1.2. Temporary Stopping Criteria
A study  sponsor representative and/or st udy medical monitorwill review evolving unblinded 
safet y data to determine if any changes shoul d be made to study  conduct.
This table describes the location of AE -related info rmation in this protocol.
Topic Location
DAIDS table describing severity of reactions Section 6.1.1.2
Definitio n of AEs Section 10.2.1
Assessment of intensity or severitySection 10.2.3
Abbreviations: AE = adverse event; DAIDS = Division of AIDS.
Changes to the planned dosing schedule must be appropriately documented and communicated 
with the study  personnel and the IRB/IEC before dosing cont inues.
CONFIDENTIAL Protocol  J2X-MC-PYAJ
256.2. Preparation/Handling/Storage/Accountability
The invest igator or desi gnee m ust confi rm appropriate storage conditions have been maintained 
during transit for all study  intervent ion received and any  discrepancies are reported and resolved 
before use of the study  interventi on.
Only participants enro lled in the study  may recei ve study  intervent ion,and only authorized site 
staff may supply or administer study  intervent ion. 
All study  intervent ion must be stored in a secure, environmentally controlled, and monitored 
(manual  or autom ated) area i n accordance with the labeled storage condit ions wit h access limited 
to the invest igator and authorized study  personnel .
The invest igatoror designee is responsible for study intervent ion accountabilit y, reconciliat ion, 
and record maintenance (i .e., recei pt, reconciliation, and final disposit ion records).
Further gui dance and information for the final disposit ion of unused study  intervent ions are 
provi ded in the pharmacy manual .
6.3. Measures to Minimize Bias: Randomi zation and Blinding
Propensity Score Matching
The non -randomized nature of a cohort study  introduces the possibilit y of bias. Therefore, the 
analysis will use propensit y score ( PS)matching using risk factors associated with 
hospi talizati on for COVID -19. The purpose of PSmatching is to create balance in the 2cohorts 
on specific relevant covariates. PS will be est imated for each patient in the bamlanivimab group 
and the comparator cohort by  the l ogist ic regressio n model, with treatm ent status as the 
dependent variable and the pre -defined independent variables considered as the potential 
confounders. The success of the PSis judged by the balance in the confounder distributi ons i t 
produces between the 2study groups. Prior to init iating the outcome analysis, the qualit y of the 
PSadjustment and associated assumptions will be evaluated. The PS model will be finalized 
prior to init iating the analysis o f the outcom e measure. Further deta ils will be provided in the 
SAP.
6.4. Study Intervention Compliance
Participants will receive study  intervent ion directly fro m the invest igator or designee, under 
medical supervisio n. The date and time of dosing will be recorded in the source documents and 
recorded in the CRF. The dose of study  intervent ion and study  parti cipant i dentificat ion will be 
confirmed at the time of dosing by a member of the study  site staff other than the person 
administering the study  interventi on.
6.5. Concomitant Therapy
Prior Treatment
Convalescent COVID -19 pl asma treatm ent is not allowed prior to enrollment.
For adol escent parti cipants, record any  vaccines received 90 days prior to signing informed 
consent.
CONFIDENTIAL Protocol  J2X-MC-PYAJ
26Concomitant Therapy
Parti cipants shoul d be treated according to standard of ca re, even as it evo lves, and medicat ions 
may be part of the treatment paradigm. Therefore, remdesivir, or baricit inib plus remdesivir, may 
be initiated as standard of care for participants hospitalized with severe disease (if available 
through the FDA EUAs )if hospi talizati on occurs following infusio n of bamlanivimab. 
If the local standard of care per written policies or guidelines ( i.e.,not just an individual clinician 
decisio n) includes lopinavir or ritonavi r, chl oroquine, hydroxychl oroquine ,or other 
investi gational agents, then init iating these during the study (after infusio n of bamlanivimab) is 
permitted but may  requi re addi tional safety  monitoring by the site.
Any medicat ion, invest igational agent, or vaccine, including over -the-counter or prescript ion 
medicines, vitamins, and/or herbal supplements , or other specific categories of interest thatthe 
participant is receiving at the time of enro llment or receives during the study  must be recorded 
along wi th
reason for use
dates of administrati on including start and end dates , and
dosage information including dose and frequency for concomitant therapy  of special 
interest .
Acetaminophen and corticosteroid use are permitted at any t ime during the study .
Other concomitant medicat ion may be considere d on a case -
by-case basis by the invest igator in 
consultation wit h the sponsor if required .
The sponsor should be contacted if there are any questions regarding conco mitant or pri or 
therapy .
6.6. Dose Modifications
No dose m odificat ions are pl anned for thi s study .
6.7. Intervention after the End of the Study
No continued access is planned after completion of this study . 
CONFIDENTIAL Protocol  J2X-MC-PYAJ
277. Discontinuation of Study Intervention and Participant 
Discontinuation/Withdrawal
Discontinuati on of  specific sites or that of the tri al as a whol e are handled as part of regulatory , 
ethical, and trial oversight considerat ions in Section10.1,Appendix 1.
7.1. Discontinuation of Study Interven tion
In rare instances, it may be necessary  for a participant to perm anent ly discont inue study  
intervent ion. If the IV infusio n is definit ively discont inued, the participant willremain in the 
study  for the rem ainder of the assessment visits through Day 90.
7.2. Participant Discontinuation/Withdrawal from the Study
A participant may withdraw fro m the study  
at any  time at his or her own request
at the request of his or her designee ( e.g.,parents or legal guardian)
at the discretion of the invest igator for safet y, behavi oral, com pliance, or administrative 
reasons , and
if enro llment in any other clinical study invo lving an invest igational product or 
enrollment in any other type o f medical research judged not to be scient ifically or 
medically co mpat ible with this s tudy.
Discontinuati on is expected to be uncommo n.
At the time of discont inuation, if possible, an early discont inuat ion phone call shoul d be 
conducted to ascertain SAEs/AEs, as described in the SoA (Secti on 1.3).
If the participant withdraws consent for disclosure of future informat ion, the sponsor may  retain 
and cont inue to use any data collected before such a withdrawal o f consent. If a participant 
withdraws fro m the study , theymay request destruction of any  samples taken and not tested, and 
the invest igator must document this in the site study records.
7.2.1. Discontinuation of Inadvertently Enrolled Participants
If the sponsor or invest igator ident ifiesa parti cipant who did not meet enrollment criteria and 
was inadvertently enrolled, then the participant shoul d be di scontinued from study  intervent ion
unless there are extenuat ing circumstances that make it medically necessary for the participant to 
continue study  intervent ion.
If the invest igator and the sponsor CRP agree it is medically appropriate to continue, the 
investigator must obtain documented approval from the sponsor CRP to allow the inadvertently 
enrolled participant to continu e in the study  with or wi thout treatm ent wi th investigational 
product.
Safety follow-up is as outlined in 
Secti on 1.3(SoA) 
Secti on 8.2(Safet y Assessments), and 
Secti on 8.3(Adverse Events and Serious Adverse Events).
CONFIDENTIAL Protocol  J2X-MC-PYAJ
287.3. Lost to Follow -Up
A participant will be considered lost to follow -up if he or she repeatedly is unavailable for
scheduled vi sits and i s unable to be contacted by  the study  site.Site personnel or desi gnee are 
expected to m ake diligent attempts to contact participants who are unavailable fora scheduled 
visit or were otherwise unable to be fo llowed up by  the si te.
Site personnel, or an independent third party , will  attem pt to collect the vital status of the 
participant wi thin legal  and ethical boundaries for all participants that received study  
intervent ion. Public sources may be searched for vital status informat ion.Ifvital status is 
determined to be deceased, this will be docum ented and the participant will not be considered 
lost to foll ow-up.Sponsor personnel will not be invo lved in any attempts to collect vital status 
inform ation.
CONFIDENTIAL Protocol  J2X-MC-PYAJ
298. Study Assessments and Procedures
Study procedures and their timing are summarized in the SoA (Secti on 1.3).
Protocol waivers or exempt ions are not allowed.
After signing of informed consent, any  immediate safet y concerns should be discussed wit h the 
sponsor immediately upon occurrence or awareness to determine if the participant should 
continue or discont inue study  intervent ion.All outlined AE or SAE reporting mustbe done as 
applic able.
Adherence to the study  design requi rements, including those specified in the SoA (Section 1.3), 
is essent ial and requi red for study conduct.
All screening evaluat ions must be com pleted and reviewed to confirm that potential part icipants 
meet all eligibilit y criteria. The invest igator will maintain a screening log to record details o f all 
participants screened and to confirm eligibilit y or record reasons for screening failure, as 
applicable.
Data for this study  will be collected from telephone calls and the EMR. 
8.1. Efficacy Assessments
Hospitalizati on events (Secti on 8.2.2 )will be used to characterize the primary outcome. 
8.2. Safety Assessments
Planned time po ints for all safet y assessments are provided in the SoA (Section 1.3).
8.2.1. Vital Signs
Vital signs will  be measured as specified in the SoA (Secti on 1.3)at the infusio n visit. Vital 
signs include
bodytemperature
bloodpressure
pulserate
respiration rate
saturati on
of peripheral  oxygen, and
supplemental oxygen fl ow rate, FiO2 if known, and method of delivery , if applicable.
Addit ional vital signs may be measured during the study if warranted, as determined by the 
investigator.
8.2.2. Hospitalization E vents
If a participant is admitted to the hospital, the participant will remain in the study and fo llow the 
procedures outlined in the SoA (Section 1.3). Hospitalizat ion is defined as ≥24 hours of acute 
care.
The date of hospitalization events will be recorded in the CRF and includes
hospitalizati on 
CONFIDENTIAL Protocol  J2X-MC-PYAJ
30emergen cy room  visit 
ICU admittance
extended care facilit y admittance, and 
discharge.
8.3. Adverse Events and Serious Adverse Events
AEswill be reported by  the parti cipant , or, when appropriate, by  a caregiver, surrogate, or the 
participant ’slegally authori zed representative. Hospitalizat ion, ED, visits, and deaths fro m 
COVID -19 are captured as endpoints and not as AEs or SAEs (see Section 10.2.1).
The invest igator and any qualified designees are responsible for detecting, documenting, and 
recording events that meet the definit ion of an AE or SAE and remain responsible for fo llowing 
up AEs that are serious, considered related to the study  intervent ion or study  procedures, or that 
caused the participant to discont inue the study  intervent ion or study .
8.3.1. Time Period and Frequency for Collecting AE and SAE Information
All AEs and SAEs will be collected from the time of signing of  the ICF until participation in 
study  has ended .
Adverse events that begin before the start of study  intervent ion but after signing of the ICF will 
be recorded on the Adverse Event CRF.
Although all AEs after signing the ICF are recorded by the site in the CRF/electronic data entry, 
SAE reporting to sponsor begins after the pa rticipan t has signed the ICF and has received study  
intervent ion. However, if an SAE occurs after signing the ICF, but prior to receiving study  
intervent ion, it needs to be reported within the SAE reporting t imeframe if it is considered 
reasonably  possibly  related to study  procedures.
All SAEs will be recorded and reported to the s ponsor or designee immediately and under no 
circumstance shoul d this exceed 24 hours of awareness , as indicated in Secti on 10.2,Appendix 
2. The invest igator will submit any updated SAE data to the sponsor within 24 hours of it being 
available.
Invest igators are not obligated to actively seek AE sor SAE safter concl usion of the study  
participat ion. 
However, if the invest igator learns of any SAE, including a death, at any t ime after 
a participant has been discharged from the study , and he or she considers the event to be 
reasonably  related to the study  intervent ion or study participat ion, the invest igator m ust prom ptly 
notify the sponsor .
8.3.2. Method of Detecting AEs and SAEs
The m ethod of recording, evaluat ing, and assessing causalit y of AE and SAE and the procedures 
for com pleting and transmitt ing SAE reports are provided in Section 10.2.
Care will be taken not to introduce bias when detecting AEs and/or SAEs. Open -ended and non -
leading verbal questioning of the participant is the preferred method to inquire about AE
occurrences.
CONFIDENTIAL Protocol  J2X-MC-PYAJ
318.3.3. Follow -Up of AEs and SAEs
After the init ial AE or SAE report, the invest igator is required to proactively fo llow each 
participant at subsequent visits or contacts. All SAEs will be fo llowed until reso lution, 
stabilization, the event is othe rwise explained, or the participant is lost to follow -up (as defined 
in Section 7.3). Further informat ion on fo llow-up procedures i s provi dedin Section 10.2.
8.3.4. Regulatory Reporting Req uirements for SAEs
Prom pt notificat ion by the invest igator to the sponsor of anSAE is essent ial so that l egal 
obligat ions and ethical responsibilit ies towards the safet y of parti cipants and the safet y of a study  
intervent ion under clinical investigat ion are m et.
The sponsor has a legal responsibilit y to notify both the l ocal regulat ory authori ty and other 
regul atory  agencies about the safet y of a study  intervent ion under clinical investigation. The 
sponsor will co mply wi th country -specific regulatory  requi rements relating to safet y reporti ng to 
the regulatory  authori ty, IRB/ IEC,and invest igators.
An invest igator who receives an invest igator safety report describing anSAE or other specific 
safet y informat ion (e.g., summary or list ing of SAEs) from the sponsor will review and then file 
it with the IB and will notify the IRB/IEC, if appropriate according to local requi rements.
8.3.5. Pregnancy
Details o f all pregnancies in female partici pants will be co llected for 90 days after pregnancy
outcom e.
If a pregnancy  is reported, the investigator should inform the sponsor within 24 hours of learning 
of the pregnancy  and shoul d follow the procedures outlined in Section 10.3, Appendix 3.
Abnorm al pregnancy outcom es, for example , spontaneous abortion, fetal death, stillbirth, 
congenital ano malies, and ectopi c pregnancy ,are considered SAEs.
8.3.6. Hypersensitivity Reacti ons
Many  drugs, but parti cularly biologic agents ,carry the ri sk of systemic hypersensit ivity 
reacti ons.
If such a react ion occurs, a dditional details describing each symptom should be provide dto the 
sponsor in the infusio n
-related reacti on/hypersensitivi ty CRF .
Sites shoul d have appropri ately  trained medical  staff and appropri ate medical equipment 
available when study  parti cipants are receiving intervent ion. It i s recommended that participants
who experience a systemic hypersensit ivityreact ion be treated per the local standard of care .
8.3.7. Infusion -related Reactions
As wi th other mAbs, infusio n-related reactions may  occur during or following IV administration . 
If an infusio n-related reacti on occurs, addi tional data describing each symptom and sign should 
be provided to the sponsor in the CRF.
This table describes the location of infusio n-related reacti on inform ation in this protocol.
Topic Location
CONFIDENTIAL Protocol  J2X-MC-PYAJ
32Special treatment considerationsSection 6.1.1
Premedication for infusions Section 6.1.1.1
Management of infusion reactions Section 6.1.1.2
DAIDS table describing severity Section 6.1.1.2
Treatment guidelines for infusion -related reactions Section 6.1.1.2
Symptom s occurring during or after infusio n of study  intervent ionmay also be defined according 
toAE categories such as acute allergic reaction (refer to DAIDS ).
8.3.8. Product Complaints
A product complaint is any written, electronic, or oral communicat ion that alleges deficiencies 
related to the identit y, qualit y, durabilit y, reliabilit y, safety, effect iveness ,or performance of a 
trial intervent ion.This may incl ude reporti ng of any medicat ion errors whether or not associated 
with an adverse event .
Sponsor collects product complaints on study  intervent ionand drug delivery systems used in 
clinical studies in order to ensure the safet y of study  parti cipants, m onitor quali ty, and to 
facilitate process and product improvements.
Parti cipants will be instructed to contact the invest igator as soon as possible if theyhavea 
complaint or probl em wi th theintervent ionso that the situation can be assessed.
NOTE: AE s/SAE sthat are associated with a product complaint will also fo llow the processes 
outlined in Sect ion 8.3.3 and Appendix 10.2 of the protocol .
Time Period for Detecting Product Complaints
Product complaints that resul t in an adverse event will be detected, documented, and reported to 
the sponsor during all periods of the study in which the intervent ion is used.
If the inv estigator l earns of any product complaint at any  time after a participant has been 
discharged from  the study , and such incident is considered reasonably related to anintervent ion
provi ded for the study , the invest igator will pro mptly notify  the sponsor.
Prompt Reporting of Product Complaints to Sponsor
Product complaints will be reported to the sponsor within 24 hours after the invest igator beco mes 
aware of the comp laint.
The Product Com plaint Form  will be sent to the sponsor by  a method desi gnated by  the sponsor.
Follow -Up of Product Complaints
Follow-up applies to all participants, including those who discont inue study  intervent ion.
The invest igator is responsible for ensuring that follow -up includes any supplemental 
investigat ions as indicated to elucidate the nature and/or causalit y of the product complaint .
New or updated informat ion will be recorded on the originally co mpleted form wit h all changes 
signed and da ted by the invest igator and submitted to the sponsor .
CONFIDENTIAL Protocol  J2X-MC-PYAJ
338.4. Treatment of Overdose
There i s no known ant idote for an overdose of bamlanivimab . 
In the event of an overdose, the invest igator should
1. c ontact the sponsor immediately
2. c loselymonitor the parti cipant for any  AEor SAE and laboratory abnormalit ies 
3. p rovidesupportive care as necessary , and
4.
docum entthe quantit y of the excess dose in the CRF.
Decisio ns regarding infusio ninterruptions or modificat ions will be made by the invest igator,in 
consultation wit hthe sponsor, based on the clinical evaluat ion of the participant.
8.5. Pharmacokinetics
This sect ion is not applicable for this study.
8.6. Pharmacodynamics
This sect ion is not applicable for this study.
8.7. Genetics
This sect ion is not applicable for this study.
8.8. Biomarkers
This sect ion is not applicable for this study.
8.9. Immunogenicity Assessments
This sect ion is not applicable for this study.
8.10. Health Economics
This sect ion is not applicable for this study.
CONFIDENTIAL Protocol  J2X-MC-PYAJ
349. Statistical Considerations
9.1. Statistical Hypotheses
The null hypothesis is that the proportions of bamlanivimab- treated and control  patients with
COVID -19-related hospit alizati onby Day 29will be similar.
9.2. Sample Size Determination
Sample Size
A sample size of at least 500 treated patients (and 500 control pat ients) will provide 
approximately  90% power to detect a treatment difference for the primary analysis, assuming the 
true rates of hospitalizat ion are 12% in the control group and at most 6 % in the treated group 
using a 2 -sided 0.05 level analysis (accounting for 5% l ost to foll ow up) . For the exploratory  
subset analyses, a comparison of the effect iveness of treatment within mult iple subsets based on 
age, com orbidities and other potential fa ctors i s of interest.  A total sample size of 3000 in each 
group will provide at least 90% power under the same assumptions within each subgroup of 
interest ,as long as the subset makes up at least 17% of the full populat ion.  Thi s also assumes no 
multiplicity adjust ment in the subset analyses.
A fulldiscussio n of power calculat ions will be provided in the SAP.
9.3. Populations for Analyses
This table defines the populations for analysis. 
Population Description
Entered All participants who sign the informed consent form .
Efficacy All participants who received study intervention and provided at least one 
post-baseline measure for the relevant endpoint. Participants will be analyzed 
according to whether they received the study intervention (treated group,
control group).
Safety All participants who received study intervention.
9.4. Statistical Analyses
The primary  analysis is a com parison of rates of hospitalization for COVID -19 between treated 
patients and the control group in the Efficacy populat ion. The pool of potential control  patients 
will be obtained fro m patients in the EMR/ claims data popul ations who meet the study  entry  
criteria and woul d qualify  for bamlanivimab treatment (but did not receive it). PS m atching using 
risk factors associated with hospi talizati on for COVID -19 will be used to create a control group 
from the pool  of potenti al control  patients that provide balance with the treated patients on the
relevant covariates. PS will be est imated for each patient in the bamlanivimab group and the 
comparator cohort by  the l ogistic regressio n model, wi th treatm ent status as the dependent 
variable and the pre -defined independent variables considered as the potential confounders. For 
the PS matching process , each eligible pat ient receiving bamlaniv imab will be matched to a 
control  patient by  a greedy  1:1 matching al gorithm ( D’Agostino 1998) with sampling without 
CONFIDENTIAL Protocol  J2X-MC-PYAJ
35replacement. The al gorithm will utilize l ogit of PS wi th a caliper of 0.2 standard deviat ions of the 
logit of the PS (Austin 2014). 
The success of the propensit y score i s judged by the balance in the confounder distributi ons i t 
produces between the 2study groups. Prior to init iating the outcome analysis, the qualit y of the 
PSadjustment and associated assumptions will be evaluated. Th e PS m odel will be finalized 
prior to init iating the analysis o f the outcom e measure. 
The primary  analysis will then be a comparison of the p roporti ons of patients with a COVID -19-
related hospi talizat ion by Day 29between the 2treatm ent groups using a logistic regressio n
modeladjust ing for vari ables a pri ori expected to be related to the outcome . 
Similarly, secondary 
analyses will include co mpar isons o f the proporti ons of  patients with COVID -19-related 
hospi talizati onsby
Days60 and 90, COVID -19-related ED vi sits, and COVID -19-related 
mortalit ythrough Days
29, 60, and 90 between the treatment groups , and will describe AEs and 
SAEs in bamlanivimab -treated pati ents.
These details will be documented in the SAP prior to 
analysis.
9.4.1. Primary Endpoint
Proporti on (percentage) of participants who experience COVID -19related hospitalization
(defined as ≥24 hours of acute care )or death by D ay 29.
9.4.1.1. Safety analysis
COVID -19 rel ated hospi talizat ion, defined as ≥24 hours of acute care, up to Days 60 and 
90
ED v isits for COVID -related causes
AEs/SAEs
Safety analyses will be conducted using the safet y popul ation described in Sect ion9.3.
All invest igational product and protocol procedure AEs will be listed, and if the frequency o f 
events allows, safet y data will be summarized using descript ive methodol ogy.
The incidence of AEs will be presented by  severi ty and by associat ion with intervent ionas 
perceived by  the invest igator , regardl ess of ascertainment of relatedness .
Safety param eters that will be assessed include AEs and SAEs .The parameters will be listed and 
summarized using standard descript ive statist ics.
9.4.2. Exploratory Analyses
Full details o f the planned exploratory  analyses will be described in the SAP and may include 
changes to the adj ustment method such as dual matching to include both prognosti c and 
propensit y matc hing. E-value or other unmeasured confounding sensit ivity analyses may also be 
included .
Addit ional exploratory  analyses of the data will be conducted as deemed appropriate. Study  
resul ts may be pool ed wi th the resul ts of other studies for safet y.
CONFIDENTIAL Protocol  J2X-MC-PYAJ
369.4.3. Subgroup Analyses
This m ay not be powered for subgroup analyses; therefore, all subgroup analyses will be treated 
as exploratory .
Subgroup analyses may be conducted for the primary  endpoint. Subgroups may  include 
age 
sex 
race
ethnicit y
baseline weight
baseline body  mass index
concomitant medicat ion
various risk factors per EUA (see section 5.1)
More details on subgroup analyses will be outlined in the study  SAP.
9.5. Interim Analyses 
Not applicable
CONFIDENTIAL Protocol  J2X-MC-PYAJ
3710. Supporting Documentation and Operational Considerations
10.1. Appendix 1: Regulatory, Ethical, and Study Oversight 
Considerations
10.1.1. Regulatory and Ethical Considerations
This study  will be conducted in accordance wit h the protocol and wi th the f ollowing:
consensus ethical principles derived from internat ional guidelines including the 
Declaration of Helsinki and Council for International Organizat ions of Medical Sciences 
International Ethical Guidelines
applicable Internati onal Counc il for Harmonizat ion (ICH) Good Clinical Practice (GCP) 
Guidelines , and
applicable laws and regulations .
The protocol, protocol amendments, ICF, IB, and other relevant documents (e .g., adverti sements) 
must be submitted to an IRB/IEC by  the invest igator and reviewed and approved by the IRB/IEC 
before the study  is init iated.
Any amendments to the protocol will require IRB/IEC approval before implementation of 
changes made to the study  design, except for changes necessary  to eliminate an immediate 
hazard to st udy part icipants.
The invest igator will be responsible for the fo llowing:
provi ding written summaries of the status of the study  to the IRB/IEC annually  or m ore 
frequently in accordance with the requirements, policies, and procedures established by 
the IRB /IEC
notifying the IRB/IEC of SAEs or other si gnificant safet y findings as required by 
IRB/IEC procedures , and
provi ding oversight of the conduct of the study  at the site and adherence to requirements 
of 21 CFR, ICH gui delines, the IRB/IEC, European regula tion 536/2014 for clinical 
studi es (if applicable), and all other applicable local regulat ions
.
Invest igator sites are compensated for participat ion in the study  as detailed in the CTA .
10.1.2. Financial Disclosure
Invest igators and sub -invest igators will provide the sponsor with sufficient, accurate financial 
inform ation as requested to allow the sponsor to submit complete and accurate financial 
certification or disclosure statements to the appropriate regulatory  authorities. Investi gators are 
responsible for providing informat ion on financial interests during the study  and f or 1 year after 
the completion of  the study .
10.1.3. Informed Consent Process
The investigator or his/her representative will explain the nature of the study , including the risks 
and benefits, to the parti cipant or theirlegally authori zed representative and answer all quest ions 
regarding the study .
CONFIDENTIAL Protocol  J2X-MC-PYAJ
38Parti cipants m ust be inform ed that thei r parti cipat ion is vo luntary. Partici pants or thei r legally  
authori zed representative will be required to sign a statement of informed consent and 
child/ado lescent assent, as appropriate, that meets the requirements of 21 CFR 50, local 
regul ations, ICH guidelines, Health Insur ance Portabilit y and Accountabilit y Act requirements, 
where applicable, and the IRB/IEC or study  center.
Due to strict respiratory  isolation policies, limited access to COVID -19 patient rooms, and 
SARS -CoV -2 transmissibilit y via droplet -contaminated paper, verbal consent ,and alternative 
methods of obtaining consent ( e.g.,by phone) will be allowed if approved by the IRB. 
If a signed paper copy  of the ICF or child/adol escent assent i s allowed by  site/insti tution policy , 
then the process of how it will be o btained and stored will need to be determined.
Any variation fro m the standard consent process due to iso lation and infect ion control should be 
sent to the IRB for approval prior to enrollment. The site will docum ent the process in their 
regul atory  files a nd demonstrate that the process has IRB concurrence or approval.
The m edical  record m ust include a statem ent that wri tten inform ed consent or child/ado lescent 
assent (if deemed appropriate by  local ethics review) was obtained before the participant was 
entered in the study  and the date the written consent or assent was obtained. The authorized 
person obtaining the informed consent or child/adolescent assent, and, if applicable, the 
individual designated to witness a verbal consent, must al so sign the ICF. The medical record 
shoul d also describe how the investigator determined that the person signing the ICF was the 
participant’s l egally authori zed representative (parent/guardian).
Parti cipants and (when applicable) their legally acceptable representative, pa rent(s), or legal 
guardi anmust be re -consented to the most current versio n of the ICF(s) during their participat ion 
in the study , per the reconsent ing guidelines as appropriate .Verbal reconsenting and alternative 
methods of obtaining consent may  be utilized if approved by  the IRB .
Minor participants must be re -consented if they reach the age of majorit y during the course of 
study , in order to continue participating.
A copy  of the ICF(s) m ust be provi ded to the participant or the participant’s legally auth orized 
representative and is kept on file.
10.1.4. Data Protection
Parti cipants will be assigned a unique ident ifier by the sponsor. Any part icipant records ,datasets ,
or tissue samples that are transferred to the sponsor will contain the identifier only; particip ant 
names or any  information which would make the participant identifiable will not be transferred.
The parti cipant must be informed that theirpersonal study -related data will  be used by  the 
sponsor in accordance wit h local data protecti on law. The l evel of disclosure m ust also be 
explained to the participant who will be required to give consent for their data to be used as 
described in the informed consent.
The parti cipant must be informed that theirmedical records m ay be examined by Clinical 
Qualit y Assurance audi tors or other authori zed personnel appo inted by  the sponsor, by  
appropriate IRB/IEC members, and by inspectors from regulatory  authori ties.
CONFIDENTIAL Protocol  J2X-MC-PYAJ
39The sponsor has processes in place to ensure data protection, informat ion securit y,and data 
integrity. These processes include appropriate contingency plan(s) for appropriate and timely 
response in the event of a data securit y breach.
10.1.5. Dissemination of Clinical Study Data
A clinical study  report will be provided for this study  and a summary  of study  information 
provi ded on publicly  available websi tes. 
10.1.6. Data Quality Assurance
Investigator responsibilities
All participant data relat ing to the study  will be recorded on printed or electroni c CRF unless 
transmitted to the sponsor or designee electronically (e .g., laboratory  data). The invest igator is 
responsible for verifying that data entries are accurate and correct by  physically  or electroni cally 
signing the CRF.
The invest igator m ust maintain accurate documentation (source data) that supports the 
inform ation entered in the CRF.
The invest igator must permit study -related m onitoring, audi ts, IRB/IEC review, and regulatory  
agency  inspect ions and provide direct access to source da ta documents.
Data monitoring and management
The monitoring planincludes
monitoring details describing strategy , for example , risk-based init iatives in operations 
and qualit y
,such as Risk Management and Mit igatio n Strategies and Analyt ical Risk-
Based Monitoring 
methods 
responsibilit ies and requi rements 
handling of nonco mpliance issues ,and 
monitoring techniques.
The sponsor or designee is responsible for the data managemen t of this study  including qualit y 
checking o f the data. The sponsor assumes accountabilit y for acti ons del egated to other 
individuals (e .g., Contract Research Organizat ions).
Study  monitors will perform  ongoing source data verification to confirm that data entered into 
the CRF by  authori zed si te personnel  are accurate, com plete, and verifiable fro m source 
docum ents. They  will also ensure that the safety  and ri
ghts of  parti cipants are being protected 
and that the study  is being conducted in accordance with t he currently approved protocol and any 
other study  agreem ents, ICH GCP, and all applicable regulatory  requi rements.
If on -site monitoring activit ies cannot occur, alternative measures will be used. Examples of 
alternat ive measures are use of techno logy for off-site monitoring or provi ding pseudonymized 
copies of  source documents to the monitor electronically. The remote source data verificat ion 
will be focused on crit ical efficacy data and important safet y data.
Records retention and audits
CONFIDENTIAL Protocol  J2X-MC-PYAJ
40Records and doc uments, including signed ICFs, pertaining to the conduct of this study must be 
retained by the invest igator for the time period outlined in the CTA unless local regulat ions or 
institutional policies requi re a l onger retenti on period.
No records may be dest royed during the retention period without the written approval of the 
sponsor. No records may  be transferred to another locat ion or party  without wri tten notificat ion 
to the sponsor.
The sponsor or its representatives will periodically check a sample of th e participant data 
recorded against source documents at the study  site. The study  may be audi ted by the sponsor or 
its representatives, and by regulatory  agencies at any  time. Investigators will be given notice 
before an audit occurs.
Data capture system
The invest igator is responsible for ensuring the accuracy, completeness, legibilit y, and timeliness 
of the data reported to the sponsor.
An EDC system  will be used in this study  for the collect ion of CRF data. The investigator 
maintains a separate source f or the data entered by  the invest igator or designee into the 
sponsor -provided EDC system.
Only symptom  assessments might be direct ly recorded by the invest igator site personnel or a 
delegate into the EDC. The direct ly entered data will serve as source docu mentation. The 
investigator will not maintain an original, separate, written ,or electronic record of these data. A 
certified copy  of the respect ive data entry will be downloaded by the invest igator for retention.
The invest igator is responsible for the ident ificat ion of any  data to be considered source and for 
the confirmat ion that data reported are accurate and complete by  signing the CRF .
Data collected via the sponsor- provided data capture system swill be stored at third parties . The 
investigator will h ave cont inuous access to the data during the study  and unt il deco mmissio ning 
of the data capture sy stem s.Prior to decommissio ning, the invest igator will receive an archival 
copy  of pertinent data for retention.
Data m anaged by  a central  vendor, such as la boratory  test data, will be stored electronically  in 
the central  vendor’s database system ,and reports will be provided to the investigator for review 
and retention. Data will subsequent ly be transferred fro m the central  vendor to the sponsor data 
warehous e.
Data from co mplaint forms submitted to sponsor will be encoded and stored in the global 
product complaint management sy stem .
10.1.7. Source Documents
Source documents provide evidence for the existence of the participant and substantiate the 
integrity of the da ta collected. Source documents are filed at the invest igator’s site.
Data reported on the CRF that are transcribed fro m source documents must be consistent with 
the source documents or the discrepancies must be explained. The investigator may need to 
reque st previ ous medical records or transfer records, depending on the study . Current m edical 
records m ust be available.
CONFIDENTIAL Protocol  J2X-MC-PYAJ
41The definit ion of what constitutes source data can be found in Sect ion10.1.6 .
10.1.8. Study and Site Start and Closure
The study  start date is the date on which the clinical study  will be open for recruit ment of 
participants.
Site Closure
The sponsor designee reserves the right to cl ose the study  site or terminate the study  at any  time 
for any  reason at the sol e discret ion of the sponsor. Study  sites will  be cl osed upon study  
completion. A study  site is considered cl osed when all required documents and study  supplies 
have b een co llected and a study -site closure visi t has been perform ed.
The invest igator may init iate study -site closure at any  time, provi ded there i s reasonable cause 
and enough notice is given in advance of the intended terminat ion.
Reasons for the early closu re of a study  site by the sponsor or investigator may  include but are 
not limited to
failure of the invest igator to comply wit h the protocol, the requirements of the IRB/IEC 
or local health authori ties, the sponsor ’sprocedures, or GCP guidelines
inadequat erecrui tment of parti cipants by  the investi gator , or
discontinuat ionof further study  intervent ion developm ent.
If the study  is prem aturely  terminated or suspended, the sponsor shall prompt ly inform  the 
investi gators , the IECs/IRBs, the regulatory  authori ties, and any contract research organizat ion(s) 
used in the study  of the reason for terminat ion or suspensio n, as specified by the applicable 
regul atory  requi rements. The investigator shall prompt ly inform  the participants and assure 
appropriate participan ttherapy  and/or foll ow-up.
10.1.9. Publication Policy
In accordance with the sponsor’s publication po licy, the results of this study  will be submitted 
for publicat ion by a peer -reviewed journal if the results are deemed to be of significant medical 
importance.
10.1.10. Investigator Information
Physicians with specialt ies, including, but not limit ed to infect ious di sease, acute or critical care, 
pulmo nary disease , immunol ogy, or other appropriate specialt iesmay participate as 
investigators.
10.1.11. Long -Term Sample Retention
Not applicable
CONFIDENTIAL Protocol  J2X-MC-PYAJ
4210.2. Appendix 2: Adverse Events: Definitions and Procedures for 
Recording, Evaluating, Follow -Up, and Reporting
10.2.1. Definition of AE
AE Definition
An AE is any  untoward m edical occurrence in a patient or clinical study  parti cipant, 
temporally  associ ated wi th the use of study  intervent ion, whether or not considered 
related to the study  intervent ion.
NOTE: An AE can therefore be any unfavorable and uni ntended si gn (including an 
abnorm al laboratory  finding), symptom, or disease (new or exacerbated) temporally 
associ ated wi th the use of study  intervent ion.
Events Meeting the AE Definition
Any abnormal laboratory  test resul ts (hematol ogy, clinical chemistry , or uri nalysis) or 
other safet y assessments (e.g., ECG, radio logical scans, and vital signs m easurements), 
including those that worsen fro m baseline, considered clinically significant in the 
medical and scient ific judgment of the investigator (i.e., not related to progression of 
underlying disease).
Exacerbat ion of a chronic or intermittent preexisting condi tion including ei ther an 
increase in frequency and/or intensit y of the condi tion.
New condi tions detected or diagnosed after study  intervent ion administration even 
though it m ay have been present before the start of the study .
Signs, symptoms, or the clinical sequelae of a suspected drug -drug interaction.
Signs, symptoms, or the clinical sequelae of a suspected overdose of either study  
intervent ion or a concomitant medicat ion. Overdose per se will not be reported as an 
AEor SAE unless it is an intent ional overdose taken wit h possible suicidal/self -
harming intent. Such overdose should be reported regardl ess of sequelae. 
“Lack of efficacy” or “failure of expected pharmacological act ion” per se will not be 
reported as an AE or SAE. Such instances will be captured in the efficacy assessments. 
However, the signs, symptoms, and/or clinical sequelae result ing fro m lack of effic acy 
will be reported as AE or SAE if they fulfill the definit ion of an AE or SAE. 
Events NOT Meeting the AE Definition
The fo llowing s tudy-specific clinical events related to COVID -19 are exempt fro m 
adverse event reporting unless the invest igator deems the event to be related to the 
administration of study  intervent ion:
ohypoxemia due to COVID -19 requiring supplemental oxygen
ohypoxemia due to COVID -19 requiring non -invasive ve ntilation or high flow 
oxygen devices , and
CONFIDENTIAL Protocol  J2X-MC-PYAJ
43orespiratory failure due to COVID -19 requiring invasive mechanical vent ilation 
or ECMO .
Any clinically  significant abnormal laboratory  findings or other abnormal safet y 
assessments which are associated with the und erlying disease, unless judged by  the 
investigator to be more severe than expected for the participant’s condit ion.
The disease/disorder being studied or expected progressio n, signs, or symptom s of the 
disease/disorder being studied, unless more severe tha n expected for the participant’s 
condi tion.
Medical or surgical procedure (e.g., endoscopy andappendectomy): the condition that 
leads to the procedure is the AE.
Situations in which an untoward medical occurrence did not occur (social and/or 
convenience a dmissio n to a hospital).
Anticipated day -to-day fluctuations of preexist ingdisease(s) or condi tion(s) present or 
detected at the start of the study  that do not worsen.
10.2.2. Definition of SAE
If an event is not an AE per definit ion above, then it cannot be an SAE even if serious condit ions 
are met (e .g., hospitalizat ion for signs/symptoms of the disease under study , death due to 
progression of disease).
AnSAE is defined as any untoward medical occurrence that, at any dose:
a.Results in death
b.Is life-threatening
The term  “life-threatening” in the definit ion of “serious”refers to an event in which the 
participant isat risk of death at the time of the event. It does not refer to an event, which 
hypotheti cally  might have caused death, if it were more severe.
c.Requires inpatient hospitalization or prolongation of existing hospitalization
In general, hospitalizat ion sig nifies that the participant has been admi tted to hospi tal
for observat ion and/or treatment that would not have been appropriate in the 
physician’s office or outpatient setting. Complicat ions that occur during hospitalization 
are AEs. If a complicat ion prol ongs hospi talizati on or f ulfills any  other seri ous cri teria, 
the event is serious. When in doubt as to whether “hospitalization” occurred or was 
necessary , the AE shoul d be considered serious.
Hospitalization for elect ive treatment of a preexist ingcondi tion that di d not worsen 
from baseline is not considered an AE.
d.Results in persistent disability/incapacity
The term disabili ty means a substant ial disrupt ion of a person’s abilit y to conduct 
norm al life f unctions.
CONFIDENTIAL Protocol  J2X-MC-PYAJ
44This definit ion is not intended to include experi ences of rel atively minor medical 
significance ,such as unco mplicated headache, nausea, vo miting, diarrhea, influenza, 
and accidental trauma (e.g., sprained ankle ),which may  interfere wi th or prevent 
everyday life functions but do not constitute a substantial disrupt ion.
e.Is a congenital anomaly/birth defect
f.Other situations:
Medical or scient ific judgment should be exercised in deciding whether SAE reporting 
is appropriate in other situations such as important medical events that may not be 
immediately  life-threatening or result in death or hospitalization but may jeopardize t he 
participant or m ay requi re medical or surgi cal intervent ion to prevent 1of the other 
outcom es listed in the above definit ion. These events should usually be considered 
serious.
Examples of such events include invasive or malignant cancers, intensive tr eatment in 
an emergency room or at home for allergic bronchospasm, blood dyscrasias or 
convulsio ns that do not result in hospitalizat ion, or development of drug dependency or 
drug abuse .
10.2.3. Recording and Follow -Up of AE and/or SAE
AE and SAE Recording
When an AE or SAE occurs, it is the responsibilit y of the invest igator to review all 
docum entati on (e.g., hospi tal progress notes, l aboratory  reports, and di agnosti cs 
reports) related to the event.
The invest igator will then record all relevant AE or SAE informat ion in the CRF.
It is notacceptable for the invest igator to send photocopies of the participant’s medical 
records to Sponsor or designee in lieu of co mpletion of the AE or SAE CRF page.
There m ay be instances when copies of medical records for certain cases are requested 
by Sponsor or desi gnee . In thi s case, all part icipant identifiers, with the exception o f 
the participant number, will be redacted on the copies of the medical records bef ore 
submissio n to Sponsor or designee .
The invest igator will attempt to establish a diagnosis of the event based on signs, 
symptoms, and/or other clinical informat ion. Whenever possible, the diagnosis (not the 
individual signs/symptoms) will be documented as the AE or SAE .
Assessment of Intensity
The invest igator will make an assessment of intensit y for each AE and SAE reported during 
the study  and assign it to 1of the fo llowing categori es, which together with serious (i.e., SAE) 
criteria on the AE CRF ( “result s in death” and “life -threatening”), are aligned wit h the DAIDS 
Table for Grading the Severit y of Adult and Pediatric Adverse Events, versio n 2.1 (July 2017) .
CONFIDENTIAL Protocol  J2X-MC-PYAJ
45Mild: Mild symptoms causing no or minimal interference with usual social and functional 
activit ies, with intervention not indicated .
Moderate: Moderate symptoms causing greater than minimal interference wit h usual 
social and f uncti onal activities, with intervention indicated .
Severe: Severe symptoms causing inabilit y to perform usual social a nd functional 
activit ies, with intervention or hospitalization indicated.
An event is defined as “serious”when i t meets at least 1 of the predefined outcomes as 
described in the definit ion of an SAE, NOT when it is rated as severe.
Assessment of Causality
The invest igator is obligated to assess the relationship between study intervent ion and 
each occurrence of each AE or SAE.
A “reasonable possibilit y” of a relationship conveys that there are facts, evidence, 
and/or arguments to suggest a causal relationship, rather than a relat ionship cannot be 
ruled out.
The invest igator will use clinical judgment to determine the relat ionship.
Alternat ive causes, such as underlying disease(s), concomitant therapy, and other risk 
factors, as well as the temporal relati onship of the event to study  intervent ion 
administration will be considered and invest igated.
The invest igator will also consult the IB and/or Product Information, for marketed 
products, in his or her assessment.
For each AE or SAE, the invest igator must document in the medical notes that he or 
she has reviewed the AE or SAE and has provided an assessment of causalit y.
There m ay be si tuations in which an SAE has occurred and the invest igator has 
minimal informat ion to include in the init ial report to Sponsor or designee . However, i t 
is very important that the investigator always make an assessment of causalit y for 
every event before the init ial transmissio n of the SAE data to Sponsor or designee .
The invest igator may change his or her opinion o f causa lity in light of follow -up 
inform ation and send anSAE follow -up report wi th the updated causalit y assessment.
The causalit y assessment i s 1of the cri teria used when determining regulatory  
reporting requirements.
Follow -Up of AEs and SAEs
The invest igator is obligated to perform or arrange for the conduct of supplemental 
measurements and/or evaluat ions as medically indicated or as requested by Sponsor or 
designee to elucidate the nature and/or causalit y of the AE or SAE as fully as possible. 
This may include addit ional laboratory  tests or investigations, histopathological 
examinat ions, or consultation with other health care professio nals.
CONFIDENTIAL Protocol  J2X-MC-PYAJ
46If a participant dies during participation in the study or during a recognized fo llow-up 
period, the invest igator will provide Sponsor or designee with a copy  of any 
postm ortem findings including histopathology. 
New or updated informat ion will be recorded in the originally co mpleted CRF.
The invest igator will submit any updated SAE data to Sponsor or designee w ithin 24 
hours of receipt of the informat ion. 
10.2.4. Reporting of SAEs
SAE Reporting via an Electronic Data Collection Tool
The primary  mechanism  for reporting an SAE will be the electronic data collect ion 
tool.
If the electronic system is unavailable, then the site will use the paper SAE data 
collect ion tool  (see next secti on) in order to report the event within 24 hours.
The site will enter the SAE data into the electronic sy stem  as soon as i t becom es 
available.
After the study  is com pleted at a given site, the electronic data collect ion tool  will be 
taken off -line to prevent the entry  of new data or changes to exist ing data.
If a site receives a report of a new SAE fro m a study  parti cipant or receives updated 
data on a previ ously  reported SAE after the electronic data collection tool has been 
taken off -line, then the site can report this informatio n on a paper SAE form (see next 
section) or to the sponsor by telephone.
Contacts for SAE reporting can be found in site training documents .
SAE Reporting via Paper CRF
Facsimile transmissio n of the SAE paper CRF is the preferred method to transmit this 
inform ation to the sponsor .
Initial notificati on via telephone does not replace the need for the invest igator to 
complete and sign the SAE CRF pages within the designated reporting time frames.
Contacts for SAE reporting can be found in site training documents .
10.2.5. Medication Error
FDA defines medication error as any  preventable event that may cause or lead to inappropriate 
medicat ion use or patient harm while the medicat ion is in the control of a healthcare provider, 
patient, or consumer ( FDA 2020b).
CONFIDENTIAL Protocol  J2X-MC-PYAJ
4710.3. Appendix 3: Contraceptive Guidance and Collection of Pregnancy 
Information
Definitions:
Women
Woman of Childbe aring Potential
A wo man is considered fertile fo llowing menarche and unt il beco ming postm enopausal unless 
perm anent ly sterile (see below).
If fertilit y is unclear (e .
g., amenorrhea in adolescents or athletes) and a menstrual cycle cannot be 
confirmed before first dose of study  intervent ion, additional eval uation shoul d be considered.
Woman not of Childbearing Potential
Women in the fo llowing categori es are not considered women of childbearing potential :
1. prem enarchal
2.
premenopausal female with either
a.docum ented hysterectomy
b.docum ented bilateral  salpingectomy , or
c.docum ented bilateral  oophorectomy .
For individuals wit h perm anent infert ility due to an alternate medical cause other than the above, 
(e.g., Müllerian agenesis, androgen insensit ivity), investi gator di scret ion shoul d be applied to 
determining study  entry .
Note: D etermina tion can com e from the si te personnel’s review of the participant’s medical 
records, medical examinat ion, or m edical history  interview.
3. P ostmenopausal  female is defined as, women with:
d.12 m onths of amenorrhea for women >55, with no need for FSH
e.12 m onths of amenorrhea for women >40 y ears old wi th FSH ≥40 m IU/mL and 
no other m edical condit ion such as anorexia nervosa and not taking medicat ions 
during the amenorrhea (e.g .,oral contraceptives, hormones, gonadotropin 
releasing hormone, ant i-estrogens, select ive estrogen receptor modulators 
(SERMs), or chemotherapy  that induced amenorrhea)
Participation in the Study
Women of child- bearing potenti al and not of child- bearing potential may participate in this 
study .
Women of child- bearing potenti al must test negative for pregnancy  prior to ini tiation of 
treatm ent as indicated by  a negative urine pregnancy  test at the scr eening visit.
Women of child- bearing potenti al who are completely  abstinent or in a same sex relat ionship ,as 
part of their preferred and usual lifest yle,must agree to either remain abst inent or stay  in a same 
sex rel ationship wit hout sexual relat ionships with males.
CONFIDENTIAL Protocol  J2X-MC-PYAJ
48All other wom en of child- bearing potential must agree to use 2forms of effective contraception, 
where at least one form is highly effective (less than 1% failure rate), for the entiret y of the 
study .
Abstinence or contraception must continue for 90 days after the l ast dose of intervent ion.
Acceptable Methods of Contraception
Highly effect ive method sof contracepti on (less than 1% failure rate) comprise but are not 
limited to
combinat ion oral contracep tives
implanted con tracepti ves,or 
intrauterine devices . 
Effect ivemethod sof contraception comprise but are not limited to diaphragms wit h spermicide 
or cervi cal sponges .
Not Acceptable Methods of Contraception
Use of m ale and female condoms as a doubl e barrier m ethod i s not considered acceptable due to 
the high failure rate when these barrier methods are combined .
Barri er protecti on m ethods wi thout concomi tant use of a spermicide are not a n effect ive or 
acceptable method of contracepti on.
Periodic abst inence (e.g., calendar, ovulat ion, symptothermal, post -ovulation methods), 
declaration of abst inence just for the duration of a trial, and withdrawal are not acceptable 
methods of contraception.
Men
Men, regardl ess of their fertilit y status, m ust agree to either remain abstinent (if this is their 
preferred and usual lifest yle) or use condoms as well as one addit ional highly effect ive method 
of contracepti on(less than 1% failure rate) or effective method of contraception with non-
pregnant women of chi ld bearing potential partners for the duration of the study  and until their 
plasma concentrations are below the level that could result in a relevant potential exposure to a 
possible fetus, predicted to be 90 day s after the l ast dose .
Men wi th pregnant par tners should use condoms during intercourse for the duration of the study 
and until the end of est imated relevant potential exposure to the fetus , predi cted to be 90 days 
after the l ast dose.
Acceptable Methods of Contraception
Highly effect ive method sof 
contraception (less than 1% failure rate) comprise, but are not 
limited to
combinat ion oral  contraceptives
implanted con tracepti ves,or 
intrauterine devices . 
CONFIDENTIAL Protocol  J2X-MC-PYAJ
49Effect ivemethod sof contraception comprise but are not limited to diaphragms wit h spermicide 
or cervical sponges .
Men and their partners may choose to use a double -barrier method of contraception thatmust 
include use of a spermicide .
Other Guidance
Men should refrain fro m sperm  donat ion for the durati on of  the study  and unt il their plasma 
concentrations are below the level that could result  in a relevant potenti al exposure to a possible 
fetus , predi cted to be 90 days after the l ast dose. 
Collection of Pregnancy Information
Male participants with partners who become pregnant
The invest igator will attempt to collect pregnancy informat ion on any male participant’s female 
partner who becomes pregnant while the male participant is in this study . This applies only to 
male participants who receive study  intervent ion.
After obtaining the necessary  signed informed consent and assent (if applicable) from the 
pregnant female partner direct ly, the investigator will record pregnancy informat ion on the 
appropriate form and submit it to the sponsor within 24 hours of learning of the partner’ s 
pregnancy. 
The female partner will also be fo llowed to determine the outcome of the pregnancy . Informati on 
on the status of the mother and child will be forwarded to the sponsor. Generally, this 
inform ation will include a follow-up of at least 5 half -lives after l ast exposure or birth. Any 
termination o f the pregnancy  will be reported including fetal status (presence or absence of 
anomalies) andindication for the procedure. 
Female participants who become pregnant
The invest igator will co llect pregnancy information on any female participant who becomes 
pregnant while part icipating in this study . The init ial informat ion will be recorded on the 
appropriate form and submitted to the sponsor within 24 hours of learning o f a participant's 
pregnancy. 
The part icipant will be fo llowed to determine the outcome of the pregnancy . The invest igator 
will co llect fo llow-up inform ation on the participant and the neonate and the informat ion will be 
forwarded to the sponsor. Generally, this information will include a follow-upof at least 5 half -
lives after last exposure or birth. Any termination of pregnancy will be reported, including fetal 
status (presence or absence of anomalies) or indication for the procedure.
While pregnancy  itself is not considered to be an AE or S AE, any  pregnancy  com plicat ion or 
elective termination o f a pregnancy  for medical  reasons will be reported as an AE or SAE. 
A spontaneous abortion (occurring at <2 0 weeks gestational age) or still birth (occurring at >20
weeks gestational age) is always considered to be an SAE and will be reported as such. 
Any post -study pregnancy -related SAE consi dered reasonably related to the study  interventi on 
by the investigator will be reported to the sponsor as described in Sect ion 8.3.4 . While the 
CONFIDENTIAL Protocol  J2X-MC-PYAJ
50investigator is not obligated to actively seek this informat ion in former study  parti cipants, he or 
she m ay learn of an SAE thro ugh spontaneous reporting.
CONFIDENTIAL Protocol  J2X-MC-PYAJ
5110.4. Appendix 4: Abbreviations
Term Definition
AC Assessment committee
ADA Anti-drug antibody
AE Adverse event
ADE Antibody -dependent enhancement
Assent Agreement from a child or other individual who is not legally capable of providing 
consent, but who can understand the circumstances and potential risks involved in 
participating in a study.
BMI Body mass index
Com plaint A complaint is any written, electronic, or oral communication that alleges deficiencies 
related to the ide ntity, quality, purity, durability, reliability, safety or effectiveness, or 
performance of an intervention.
Com pliance Adherence to all study -related, good clinical practice (GCP), and applicable regulatory 
requirements.
CRF Case report form
CRP Clinical research physician: individual responsible for the medical conduct of the study. 
Responsibilities of the CRP may be performed by a physician, clinical research 
scientist, global safety physician ,or other medical officer.
CTA Clinical trial agreem ent
DAIDS Division of AIDS
DMC Data monitoring committee
ECG Electrocardiogram
ED Emergency department
EDC Electronic data capture
EMR Electronic medical record
Enroll The act of assigning a participant to a treatment. Participants who are enrolled in the 
study are those who have been assigned to a treatment.
Enter Participants entered into a study are those who sign the informed consent form directly 
or through their legally acceptable representatives.
EUA Emergency Use Authorization
FiO2 Fraction of inspired oxygen in the air
CONFIDENTIAL Protocol  J2X-MC-PYAJ
52GCP Good clinical practice
IB Investigator’s Brochure
ICF Informed consent form
ICH International Council for Harmonisation
IMP Investigational Medicinal Product
Informed consent A process by which a participant voluntarily confirms his or her willingness to 
participate in a particular study, after having been informed of all aspects of the study 
that are relevant to the participant’s decision to participate. Informed consent is 
documented by means of a written, s igned ,and dated informed consent form .
Interim analysis An interim analysis is an analysis of clinical study data, separated into treatment groups, 
that is conducted before the final reporting database is created/locked.
Intervention A pharmaceutical fo rm of an active ingredient or placebo being tested or used as a 
reference in a clinical trial, including products already on the market when used or 
assembled (formulated or packaged) in a way different from the authorized form, or 
marketed products used f or an unauthorized indication, or marketed products used to 
gain further information about the authorized form.
IRB/IEC Institutio nal Review Boards/Independent Ethics Committees
IV Intravenous
IWRS Interactive web -response sy stem
Legal representative An individual or judicial or other body authorized under applicable law to consent, on 
behalf of a prospective participant, to their participation in the clinical study.
Medication error A medication error is any preventable event that may cause or lead t o inappropriate 
medication use or patient harm while the medication is in the control of a healthcare 
provider, patient, or consumer (FDA 2020 b).
Mabs Monoclonal antibodies
NP Nasophary ngeal
Participant Equivalent to CDISC term “subject”: an individual who participates in a clinical trial, 
either as recipient of an investigational medicinal product or as a control
PK/PD Pharmacokinetics/pharmacodynamics
PS Propensity score
SAE Serious adverse event
SAP Statistical analysis plan
SARS Severe acute respiratory  syndrome
CONFIDENTIAL Protocol  J2X-MC-PYAJ
53Screen The act of determining if an individual meets minimum requirements to become part of 
a pool of potential candidates for participation in a clinical study. 
SpO2 Saturatio n of peripheral oxygen
CONFIDENTIAL Protocol  J2X-MC-PYAJ
5411. References
Aoki FY, Macleod MD, Paggiaro P, et al.Early administration of oral oseltamivir increases the 
benefits of influenza treatment. J Antimicrob Chemother. 2003; 51(1) : 123-129.
https://doi .org/10.1093/j ac/dkg007.
Austin PC. A co mpar ison of 12 algorithms for mat ching on the propensit y score. StatMed.
2014;
33(6) : 1057 -1069. https://doi.org/10.1002%2Fsim.6004 .
D’Agostino RB. Propensit y score methods for bias reduction in the co mpar ison of a treatment to 
a non -rando mized control group .StatMed. 1998; 17(19): 2265- 2281.
Divisio n of AIDS (DAIDS) Table for Grading the Severit y of Adult and Pediatric Adverse 
Events. National Inst itute of Allergy and Infect ious Di seases. Nati onal Insti tutes of Heal th. US 
Departm ent of Healt h and Human Services. Corrected version 2. 1. July 2017. Accessed 
October 05, 2020 .https://rsc.niaid.nih.gov/sites/default/files/daidsgradingcorrectedv21.pdf .
Duan K, Liu B, Li, C, et al. Effect iveness of convalescent plasma therapy in severe COVID -19 
patients. PNAS . 2020. https://doi.org/10.1073/pnas.2004168117.
[FDA 2020a] U.S. Food and Drug Administration. Fact Sheet for Health Care Providers 
Emergency  Use Authori zation (EUA) of Bam lanivimab. Accessed December 18, 2020. 
https://www.fda.gov/media/143603/download .
[FDA 2020b ] U.S. F ood and Drug Administration. Medi cation Errors Rel ated to CDER -
Regulated Drug Products . Accessed December 17, 2020. https://www.fda.gov/drugs/drug -
safet y-and-availabilit y/medicat ion-errors -related- cder-regulated -drug-
products#:~:text=FDA%20defines% 20a%20medicati on%20error,provi der%2C%20pati ent%2
C%20or%20consumer .
FDA resource page. COVID -19: Developing drugs and biological products for treatm entor 
prevent ion gui dance for industry .Food and Drug Administration web site. Accessed October 
05, 2020. https:// www.fda.gov/regulatory -informatio n/search -fda-guidance -docum ents/covi d-
19-developing -drugs -and-biological -products -treatment - or-prevent ion.
Hoffmann M, Kleine -Weber H, Schroeder S, et al. SARS -CoV -2 cell entry  depends on ACE2 
and TMPRSS2 and is blo cked by a clinically proven protease inhibitor .Cell. 2020;181:1 -10. 
doi:10.1016/j .cell.2020.02.052.
Liu Y, Sun W, Li J, et al.Clinical features and progressio n of acute respiratory  distress syndro me 
in coronavirus disease 2019. medRxiv . Posted February  27, 2020. Preprint.
https://doi .org/10.1101/2020.02.17.20024166 . 
Shen C, Wang Z, Zhao F, et al. Treatm ent of  5 critically Ill patients with COVID -
19 w ith 
convalescent p lasma. JAMA . Published March 27, 2020. doi:10.1001/j ama.2020.4783.
Leo Document ID = 8ac6f859-6b0b-4bf6-8d30-2c0017eaee3f
Approver: 
Approval Date & Time: 18-Dec-2020 23:02:04 GMT
Signature meaning: Approved
Approver: 
Approval Date & Time: 18-Dec-2020 23:42:05 GMT
Signature meaning: Approved
PPD
PPD